DOI: https://dx.doi.org/10.18203/2319-2003.ijbcp20221817
Published: 2022-08-24

Assessment of the pharmacokinetics, safety, and tolerability of levothyroxine sodium in healthy Indian volunteers

Swati A. Biswas, Anadya Prakash Tripathi, Dyotona Sen-Roy

Abstract


Background: Few studies have assessed the pharmacokinetics of various marketed formulations of levothyroxine available in the Indian market. Here, we assessed the pharmacokinetics and safety of Thyronorm® 100 in healthy Indian volunteers.

Methods: The primary and secondary objectives were to determine the pharmacokinetic profile and to monitor safety and tolerability of 600 µg of levothyroxine, respectively. Eligible subjects received a single oral dose of 6×100 µg of levothyroxine, and pharmacokinetic profiles were monitored up to 432 hours post-dose. Safety assessments included exposure of study drug and incidence of adverse events (AEs) and serious AEs. The mean plasma concentration of LT4 versus time profile was presented on both untransformed and log-transformed scales.

Results: Of 20 enrolled subjects, 1 was discontinued due to an AE of pain, unrelated to study drug. The mean [standard deviation (SD)] age and body mass index of subjects were 35.7 (6.33) years and 25.0 (3.0) kg/m2, respectively. Following baseline correction, the mean maximum observed drug concentration (Cmax) and area under the plasma concentration-time curve measured to the last quantifiable concentration (AUC0-t) of free thyroxine were found to be 68.4 (12.09) ng/ml and 6760.0 (2065.05) ng×hr/ml, respectively, with an elimination half-life (t1/2) of 205.6 (180.26) hrs and a residual area of 24.6%. The median time to first observed maximum drug concentration (Tmax) was 2.5 (1.5-2.5) hrs.

Conclusions: These parameters were in accordance with those of other marketed formulations and confirmed the pharmacokinetics and safety of Thyronorm® 100 in healthy volunteers from India.


Keywords


Levothyroxine, Intra-subject variability, Therapeutic index

Full Text:

PDF

References


Taylor PN, Albrecht D, Scholz A, Gutierrez-Buey G, Lazarus JH, Dayan CM, et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. 2018;14(5):301-16.

Unnikrishnan AG, Kalra S, Sahay RK, Bantwal G, John M, Tewari N. Prevalence of hypothyroidism in adults: An epidemiological study in eight cities of India. Indian J Endocrinol Metab. 2013;17(4):647-52.

Blakesley V, Awni W, Locke C, Ludden T, Granneman GR, Braverman LE. Are bioequivalence studies of levothyroxine sodium formulations in euthyroid volunteers reliable? Thyroid. 2004;14(3):191-200.

Mithal A, Dharmalingam M, Tewari N. Are patients with primary hypothyroidism in India receiving appropriate thyroxine replacement? An observational study. Indian J Endocrinol Metab. 2014;18(1):83-8.

Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, et al. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid. 2014;24(12):1670-751.

Glaxo Smith Kline. Bioequivalence of Two Levothyroxine Tablet Formulations in Healthy Indian Volunteers, 2012. Available at: https://clinicaltrials.gov/ct2/show/record/NCT01536678?view=record. Accessed on 10 April 2022.

Bhupathi C, Vajjha VHG. Sample size recommendation for a bioequivalent study. Statistica. 2017;77:65-71.

Wuxu Data. Public Assessment Report Decentralised Procedure. Procedure Number: DE/H/5712/001-011/DC Tillomed Laboratories Limited, 2021. Available at: https://file.wuxuwang.com/hma.pdf. Accessed on 10 April 2022.

Government of UK. Public Assessment Report Levothyroxine 12.5 microgram Tablets, Levothyroxine 25 microgram Tablets and Levothyroxine 75 microgram Tablets. UK License number: PL 00289/1971-73). TEVA UK Ltd, 2022. Available at: https://www.gov.uk/guidance/find-product-information-about-medicines. Accessed on 10 April 2022.

Colucci P, Yue CS, Ducharme M, Benvenga S. A Review of the Pharmacokinetics of Levothyroxine for the Treatment of Hypothyroidism. Eur Endocrinol. 2013;9(1):40-7.

Numani D, Scarsi C, Ducharme MP. Levothyroxine soft capsules demonstrate bioequivalent pharmacokinetic exposure with the European reference tablets in healthy volunteers under fasting conditions. Int J Clin Pharmacol Ther. 2016;54(2):135-43.

Hostalek U, Uhl W, Wolna P, Kahaly GJ. New levothyroxine formulation meeting 95-105% specification over the whole shelf-life: results from two pharmacokinetic trials. Curr Med Res Opin. 2017;33(2):169-74.

Lipp HP, Hostalek U. A new formulation of levothyroxine engineered to meet new specification standards. Curr Med Res Opin. 2019;35(1):147-50.

Concordet D, Gandia P, Montastruc JL, Mélou A, Lees P, Ferran A, et al. Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients? Clin Pharmacokinet. 2019;58(7):827-33.

Concordet D, Gandia P, Montastruc JL, Mélou A, Lees P, Ferran AA, et al. Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One? Clin Pharmacokinet. 2020;59(1):1-5.

Yu LX, Jiang W, Zhang X, Lionberger R, Makhlouf F, Schuirmann DJ, et al. Novel bioequivalence approach for narrow therapeutic index drugs. Clin Pharmacol Ther. 2015;97(3):286-91.